micro-community-banner
 
  • Saved

2yr
The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease - PubMed

The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36902326/

The study of osteoblast (OB) metabolism has recently received increased attention due to the considerable amount of energy used during the bone remodeling process. In addition to glucose, the main...

Conclusion: We describe the main metabolic pathways governing OBs' fate and functions, both in physiological and pathological malignant conditions. In particular, we focus on multiple myeloma (MM) bone disease, which is characterized by a severe imbalance in OB differentiation due to the presence of malignant plasma cells into the bone...

  • Saved

2yr
Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma - Leukemia

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma - Leukemia

Source : https://www.nature.com/articles/s41375-023-01824-0

Pseudo-progression and flare-up phenomena constitute a novel diagnostic challenge in the follow-up of patients treated with immune-oncology drugs. We present a case study on pulmonary flare-up after Idecabtagen Vicleucel (Ide-cel),...

Conclusion: Our study highlights a Th17.1 driven autoimmune phenomenon after CAR T, which may be misinterpreted as disease relapse, and that imaging with multiple PET tracers and scRNA-seq could help in this diagnostic dilemma.

  • Saved

2yr
Peripheral Nerve Stimulation for Back Pain in Patients With Multiple Myeloma as Bridge Therapy to Radiation Treatment: A Case Series

Peripheral Nerve Stimulation for Back Pain in Patients With Multiple Myeloma as Bridge Therapy to Radiation Treatment: A Case Series

Source : https://www.neuromodulationjournal.org/article/S1094-7159(23)00027-2/fulltext

Patients with spinal lesions or vertebral compression fractures from multiple myeloma often present with back pain that restricts their ability to lie flat and prevents them from undergoing cancer treatment....



Conclusions: PNS can effectively treat low back pain secondary to myeloma-related spinal lesions as a bridge therapy to radiation. The use of PNS is a promising option for back pain from other primary or metastatic tumors. Further research is needed into the use of PNS for cancer-related back pain.

  • Saved

2yr
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience

Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience

Source : https://www.sciencedirect.com/science/article/abs/pii/S2666636723000362?via=ihub

Available online 18 January 2023 Author links open overlay panel Taxiarchis Kourelis 1 , , , , , , , , , , , , , , , , ,...


Conclusions: This study is the first attempt to evaluate existing issues with CAR-T access for patients with MM and the variability and challenges in patient selection. Integrating ethical resource allocation strategies, similar to those described here, into formal institutional policies would help streamline access to CAR-T therapy and...

  • Saved

2yr
Cell-based gene therapy in multiple myeloma

The CAR T-cell field in MM has made several strides since the first BCMA-targeted CAR was developed nearly 10 years ago. Results from the pivotal phase 2 KarMMa study of idecabtagene vicleucel (ide-cel) shows promise with rapid, deep, and durable responses in patients with triple-class-exposed relapsed and refractory myeloma.

The ORR at primary analysis was 72% at a median follow-up of 13.2 months. Furthermore, 55% of patients experienced a very good partial response (VGPR) or better, with 93% of evaluable patients being MRD negative.

Ide-cel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. It is indicated in adult patients with R/R multiple myeloma following 4+ prior lines of therapy. These prior lines of therapy include an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Ide-cel was approved by the FDA in March 2021, and each dose is a customized treatment developed based on the patient’s own T-cells. These T-cells are collected and genetically modified to incorporate a new gene that targets and kills myeloma cells. Modified cells are infused into the patient.

What have your experiences with ide-cel been compared with other BRMA-targeted CAR T cell therapy? In your opinion/experience, will ide-cel have a prominent place in R/R multiple myeloma?

  • 2yr
    Carvyktri seems to outperform Abecma in OS, PFS, ORR but usage has been heavily limited my manufacturing slot availability. Have used both CAR-T products in place of transplant for good Show More
  • 2yr
    i think Ide-Cel has potential role IN THE PLACE OF TRANSPLANT /instead of transplant; otherwise, its a very valuable tretament option; concern si getting slots, enrollment speed is a concern(slow Show More

Show More Comments